Navigation Links
DrugRisk Update: Court Asks for Pradaxa Lawsuit Test Cases
Date:4/25/2013

Chicago, IL (PRWEB) April 25, 2013

The drug safety advocates at DrugRisk.com are alerting patients taking the blood thinner Pradaxa of updated legal news on the site. A federal judge overseeing hundreds of lawsuits alleging Pradaxa internal bleeding has asked lawyers to prepare a small number of cases for evidence gathering and early test trials.

The goal of DrugRisk is to improve patient safety by sharing the latest warnings, recalls, studies and legal news related to prescription drugs. Visitors can see if others are experiencing similar side effects and if legal action is under way.

Pradaxa was launched in 2010 to prevent strokes in patients with atrial fibrillation. Experts, however, have disagreed over whether it presents dangerous risks for internal bleeding. The FDA recently advised that Pradaxa is no more dangerous than traditional blood thinner warfarin*.

The Institute for Safe Medication Practices, however, warned that patients suffering Pradaxa bleeding are nearly 5 times as likely to die than those with bleeding from warfarin. They also named anticoagulants like Pradaxa among the most dangerous drugs**.

With over 260 patients so far having filed a Pradaxa lawsuit alleging internal bleeding, cases have been consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Now, DrugRisk has added a Case Management Order from Judge David Herndon, who is overseeing the litigation, asking that lawyers prepare 16 cases for early discovery and the selection of early trials, or “bellwether” cases***.

Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.

For more information on the research, Pradaxa side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
**Instutute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
***ilsd.uscourts.gov/opinions/ilsd_live.3.12.md.2385.2323437.0.pdf#search="pradaxa"

Read the full story at http://www.prweb.com/releases/side-effects-of-pradaxa/2013-pradaxa-lawsuit/prweb10669308.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Adds Update From Court Ordering Mediation of Stryker Hip Lawsuits
2. DrugRisk Announces Launch of Byetta Cancer Resource Center
3. DrugRisks Update: Federal Court Schedules First Mirena Lawsuit Hearing
4. DrugRisk Announces Addition of Januvia Cancer Resource Center
5. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
6. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
7. DrugRisk Announces Launch of DePuy Hip Resource Center
8. DrugRisk Update: Mirena Maker Asks to Keep Lawsuits With Local Court, Judge
9. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
10. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
11. DrugRisk Adds Study Showing Pradaxa May Increase Viral Infection Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... ... , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the homeopathic ... Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength is ... , Removal of the homeopathic element , Adding their patented ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. ... GlycoMark test throughout the Northeast U.S. , GlycoMark is the only clinically ... GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic excursions, ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical ... Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord ... donate. , “Women’s Hospital at Renaissance has been a collection partner for the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology: